Arbutus Biopharma (ABUS) EBT Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted EBT Margin of 94.74% for Q1 2026, up 122.47% sequentially from 421.6% in Q4 2025, and up 148533.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) EBT Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported EBT Margin for 14 years, with the latest figure at 94.74% in Q1 2026.
- Quarterly EBT Margin rose 148533.0% year-over-year to 94.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 83.6% (up 128742.0% YoY) and the FY2025 annual result came in at 1530.09%, down 39704.0% from the prior year.
- EBT Margin grew to 94.74% in Q1 2026 per ABUS's latest filing, from 421.6% in the prior quarter.
- Over five years, EBT Margin peaked at 94.74% in Q1 2026 and troughed at 1472.89% in Q3 2024.
- A 5-year average of 620.98% and a median of 421.6% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2026: EBT Margin plunged 104129 bps in 2024, then jumped 148533 bps in 2026.
- Over 5 years, EBT Margin stood at 351.19% in 2022, then tumbled by 156 bps to 900.33% in 2023, then grew by 8 bps to 824.52% in 2024, then soared by 49 bps to 421.6% in 2025, then surged by 122 bps to 94.74% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 94.74%, 421.6%, and 1461.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | -506.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -506.90% |
| Mar 31, 2026 | 94.74% |
| Dec 31, 2025 | -421.60% |
| Sep 30, 2025 | -1,461.25% |
| Jun 30, 2025 | 23.30% |
| Mar 31, 2025 | -1,390.59% |
| Dec 31, 2024 | -794.09% |
| Sep 30, 2024 | -1,472.89% |
| Jun 30, 2024 | -1,146.47% |
| Mar 31, 2024 | -1,165.93% |
| Dec 31, 2023 | -900.33% |
| Sep 30, 2023 | -431.60% |
| Jun 30, 2023 | -367.53% |
| Mar 31, 2023 | -244.34% |
| Dec 31, 2022 | -351.19% |
| Sep 30, 2022 | -295.14% |
| Jun 30, 2022 | -99.66% |
| Mar 31, 2022 | -89.98% |
| Dec 31, 2021 | -665.03% |
| Sep 30, 2021 | -573.59% |